WATERVIEW PLAZA, SUITE 310, PARSIPPANY, NJ
Announces Second Quarter 2025 Financial and Business Results
Announces First Quarter 2025 Financial and Business Results
Costs of Shutting Down or Selling Parts of the Business, Other Events
Non-Reliance on Financial Statements
Material disclosure
To No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
Submission of Matters to a Vote of Security Holders
Q2
Q1
Amended Annual Report
FY 2024
Q3
FY 2023 amended
Notice of Exempt Offering of Securities
RW
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities
S-1
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload
S-8 POS